Abstract
Molecular profiling of cancers can potentially yield novel gene markers of therapeutic prediction, which would aid our ability to tailor targeted therapy regimens specific to each patient. Public data from gene expression profiling may yield clues as to what oncogenic signaling pathways are deregulated in cancers, and what drugs may effectively counteract the aberrant gene regulation patterns observed. Data are also available on panels of cancer cell lines, which have been both profiled at the gene expression level and extensively characterized for drug responses, allowing us to identify geneto- drug correlations. Profiling tumors from patients undergoing adjuvant or neoadjuvant drug treatment can also yield markers of therapeutic response. In this review, we will examine recent studies aimed at our eventually being able to use the molecular profile of a tumor to predict drug response. The profiling data from these studies is publicly available, and can be re-examined by researchers with different questions in mind, offering us a large number of biomarker candidates that could potentially be tested in the clinical setting.
Keywords: Gene expression profiling, oncogenic signatures, drug response prediction, molecular profile of a tumor, gene regulation, CONNECTIVITY MAP, oncogenic signaling pathways, ER+) breast tumors, biomarkers, gene transcription.
Current Drug Targets
Title:Molecular Classification and Drug Response Prediction in Cancer
Volume: 13 Issue: 12
Author(s): Chad J. Creighton
Affiliation:
Keywords: Gene expression profiling, oncogenic signatures, drug response prediction, molecular profile of a tumor, gene regulation, CONNECTIVITY MAP, oncogenic signaling pathways, ER+) breast tumors, biomarkers, gene transcription.
Abstract: Molecular profiling of cancers can potentially yield novel gene markers of therapeutic prediction, which would aid our ability to tailor targeted therapy regimens specific to each patient. Public data from gene expression profiling may yield clues as to what oncogenic signaling pathways are deregulated in cancers, and what drugs may effectively counteract the aberrant gene regulation patterns observed. Data are also available on panels of cancer cell lines, which have been both profiled at the gene expression level and extensively characterized for drug responses, allowing us to identify geneto- drug correlations. Profiling tumors from patients undergoing adjuvant or neoadjuvant drug treatment can also yield markers of therapeutic response. In this review, we will examine recent studies aimed at our eventually being able to use the molecular profile of a tumor to predict drug response. The profiling data from these studies is publicly available, and can be re-examined by researchers with different questions in mind, offering us a large number of biomarker candidates that could potentially be tested in the clinical setting.
Export Options
About this article
Cite this article as:
J. Creighton Chad, Molecular Classification and Drug Response Prediction in Cancer, Current Drug Targets 2012; 13 (12) . https://dx.doi.org/10.2174/138945012803530143
DOI https://dx.doi.org/10.2174/138945012803530143 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Discovery and Applications of Disulfide-Rich Cyclic Peptides
Current Topics in Medicinal Chemistry Preface [Hot Topic: Multifunctional Drug Targets (Executive Editors: H.E. Tibbles and A.O. Vassilev)]
Current Pharmaceutical Design Nitric Oxide-Derived Oxidants with a Focus on Peroxynitrite: Molecular Targets,Cellular Responses and Therapeutic Implications
Current Pharmaceutical Design Impact of Cytokines and Chemokines on Alzheimer’s Disease Neuropathological Hallmarks
Current Alzheimer Research A Pan-Cancer Review of <i>ALK</i> Mutations: Implications for Carcinogenesis and Therapy
Current Cancer Drug Targets The Therapeutic Potential of Sigma (σ) Receptors for the Treatment of Central Nervous System Diseases: Evaluation of the Evidence
Current Pharmaceutical Design Immunophilin Dysfunction and Neuropathology
Current Medicinal Chemistry Systems Biology of Apoptosis and Survival: Implications for Drug Development
Current Pharmaceutical Design ADAM Proteins- Therapeutic Potential in Cancer
Current Cancer Drug Targets The Effects of 1,3,5-trisubstituted Indole Derivatives on Cell Growth, Apoptosis and MMP-2/9 mRNA Expression of MCF-7 Human Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Monoamine Oxidase Inhibitors as Neuroprotective Agents in Age-Dependent Neurodegenerative Disorders
Current Pharmaceutical Design Differential Regulation of Neurotoxin in HIV Clades: Role of Cocaine and Methamphetamine
Current HIV Research The Paths to Neurodegeneration in Genetic Parkinson's Disease
CNS & Neurological Disorders - Drug Targets The Role of the Anti-Amyloidogenic Secretase ADAM10 in Shedding the APP-like Proteins
Current Alzheimer Research Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal Cell Survival Signaling in Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Natural Product-Inspired Synthesis of Thiazolidine and Thiazolidinone Compounds and their Anticancer Activities
Current Pharmaceutical Design Anticancer Therapeutic Strategies Based on CDK Inhibitors
Current Pharmaceutical Design Nose to Brain Delivery of Nanoformulations for Neurotherapeutics in Parkinson’s Disease: Defining the Preclinical, Clinical and Toxicity Issues
Current Drug Delivery MET and ALK as Targets for the Treatment of NSCLC
Current Pharmaceutical Design